Other News To Note
• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., said an article published in PLOS One, based on a study conducted at the Moffitt Cancer Center examining the immunologic mechanism of PV-10 in murine models of breast cancer and melanoma, concluded intralesional administration of the drug reduced the growth of directly injected tumors and led to the induction of a robust antitumor T-cell response.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST